ROR1 and prostate neoplasm: We found that, in comparison to untreated LNCaP C42 prostate tumors, which express the ROR1 tumor antigen at various levels, CAR-targeted tumors in both treatment groups (adoptively transferred T cells or nanoparticle-programmed T cells) eventually developed ROR1 low/negative immune-escape variants (Fig. 7i).